It has been reported that mortality risk is increased in untreated vs treated patients with GHD (18) and that patients with MPHD have an increased CV mortality and morbidity risk, owing to unreplaced GH, the aetiology of hypopituitarism and non-physiological replacement therapy of other hormone deficiencies (19, 20, 21). The gene discussed is GH1; the disease is hypopituitarism.